# Cannabidiol as add-on Therapy for Children With Refractory Epilepsy (CBD-uN1que), a High-quality Individualized Approach: a Series of N-of-1 Trials

> **NCT07668856** · PHASE3 · RECRUITING · sponsor: **UMC Utrecht** · enrollment: 50 (estimated)

## Conditions studied

- Refractory Epilepsy in Children
- Refractory Epilepsy
- Epilepsy

## Interventions

- **DRUG:** Cannabidiol (CBD) oral solution
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07668856
- **Lead sponsor:** UMC Utrecht
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-06
- **Primary completion:** 2027-11
- **Final completion:** 2027-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-06-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07668856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07668856, "Cannabidiol as add-on Therapy for Children With Refractory Epilepsy (CBD-uN1que), a High-quality Individualized Approach: a Series of N-of-1 Trials". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07668856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*